The Advisory Committee on Immunization Practices recommends that routine HPV vaccination be initiated for the 9vHPV at which age group?

The Advisory Committee on Immunization Practices (ACIP) recommends that routine HPV vaccination, specifically with the 9-valent human papillomavirus vaccine (9vHPV), be initiated for preteens at the ages of 11 to 12 years. This age group is targeted because the vaccine is most effective when given before the onset of sexual activity, which is why early vaccination is emphasized.

The rationale for recommending vaccination at 11 to 12 years of age includes several factors:

1. It allows children to be vaccinated before they become sexually active, providing protection against HPV-related cancers and diseases.

2. The ACIP also allows vaccination to start as early as 9 years of age, but the routine recommendation is specifically for the 11-12 year age group to align with other adolescent vaccines.

3. Vaccination in this age range is supported by clinical studies showing robust immune response and effectiveness in preventing HPV-related diseases.

This age range also coincides with other recommended vaccinations during adolescence, making it a convenient time for healthcare providers to ensure comprehensive immunization coverage. While individuals older than this age can still receive the vaccine, the routine recommendation specifically targets 11 to 12 years old, emphasizing early intervention for long-term health benefits.